FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601478625> ?p ?o ?g. }

• W2601478625 endingPage "58162" @default.
• W2601478625 startingPage "58152" @default.
• W2601478625 abstract "// Tae-Wook Chung 1 , Eun-Young Kim 1, 2 , Seok-Jo Kim 3 , Hee-Jung Choi 1 , Se Bok Jang 4 , Keuk-Jun Kim 5 , Sun-Hyung Ha 3 , Fukushi Abekura 3 , Choong-Hwan Kwak 3 , Cheorl-Ho Kim 3 and Ki-Tae Ha 1, 2 1 School of Korean Medicine, Healthy Aging Korean Medical Research Center, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Republic of Korea 2 Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National University, Yangsan, Gyeongsangnam-do 50612, Republic of Korea 3 Department of Biological Science, Sungkyunkwan University, Suwon, Kyunggi-do 16419, Republic of Korea 4 Department of Molecular Biology, College of Natural Sciences, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea 5 Department of Clinical Pathology, TaeKyeung University, Gyeongsan 38547, Republic of Korea Correspondence to: Cheorl-Ho Kim, email: chkimbio@skku.edu Ki-Tae Ha, email: hagis@pusan.ac.kr Keywords: sialyllactose, milk, oligosaccharides, angiogenesis, VEGF receptor-2 Received: May 31, 2016     Accepted: February 15, 2017     Published: March 14, 2017 ABSTRACT The oligosaccharides in human milk have various biological functions. However, the molecular mechanism(s) underlying the anti-angiogenic action of sialylated human milk oligosaccharides (HMOs) are still unclear. Here, we show that siallylactose (SL) found in human milk can inhibit the activation of vascular endothelial growth factor (VEGF)-mediated VEGF receptor-2 (VEGFR-2) by binding to its VEGF binding site (second and third IgG-like domains), thus blocking downstream signal activation. SL also inhibits growth of VEGF-stimulated endothelial cells. In endothelial cells treated with VEGF, SL diminished tube formation, migration, and the arrangement of actin filament. In addition, SL clearly suppressed VEGF-induced neovascularization in an in vivo Matrigel plug assay. Notably, SL prevented the growth of tumor cells, and angiogenesis on tumor tissues in in vivo mice models allotransplanted with Lewis lung carcinoma, melanoma, and colon carcinoma cells. Taken together, we have demonstrated that the sialylated milk oligosaccharide sialyllactose functions as an inhibitor of angiogenesis through suppression of VEGF-mediated VEGFR-2 activation in endothelial cells, Accordingly, it could be a novel candidate for the development of anti-angiogenic drugs without any side effects." @default.
• W2601478625 created "2017-04-07" @default.
• W2601478625 creator A5005944401 @default.
• W2601478625 creator A5015118475 @default.
• W2601478625 creator A5032711040 @default.
• W2601478625 creator A5037130722 @default.
• W2601478625 creator A5044651368 @default.
• W2601478625 creator A5077539926 @default.
• W2601478625 creator A5082085481 @default.
• W2601478625 creator A5082614396 @default.
• W2601478625 creator A5084517193 @default.
• W2601478625 creator A5089073003 @default.
• W2601478625 creator A5091015282 @default.
• W2601478625 date "2017-03-14" @default.
• W2601478625 modified "2023-10-18" @default.
• W2601478625 title "Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression" @default.
• W2601478625 cites W1877735299 @default.
• W2601478625 cites W1961766403 @default.
• W2601478625 cites W1967621966 @default.
• W2601478625 cites W1995031154 @default.
• W2601478625 cites W2000064849 @default.
• W2601478625 cites W2027599993 @default.
• W2601478625 cites W2037379652 @default.
• W2601478625 cites W2045510646 @default.
• W2601478625 cites W2053213651 @default.
• W2601478625 cites W2053791316 @default.
• W2601478625 cites W2056802932 @default.
• W2601478625 cites W2077129920 @default.
• W2601478625 cites W2092156814 @default.
• W2601478625 cites W2105795671 @default.
• W2601478625 cites W2110335769 @default.
• W2601478625 cites W2112572787 @default.
• W2601478625 cites W2117692326 @default.
• W2601478625 cites W2122118178 @default.
• W2601478625 cites W2128956666 @default.
• W2601478625 cites W2143926802 @default.
• W2601478625 cites W2144707486 @default.
• W2601478625 cites W2151392138 @default.
• W2601478625 cites W2157542971 @default.
• W2601478625 cites W2171521392 @default.
• W2601478625 cites W2288139400 @default.
• W2601478625 cites W2342822806 @default.
• W2601478625 doi "https://doi.org/10.18632/oncotarget.16192" @default.
• W2601478625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5601640" @default.
• W2601478625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28938544" @default.
• W2601478625 hasPublicationYear "2017" @default.
• W2601478625 type Work @default.
• W2601478625 sameAs 2601478625 @default.
• W2601478625 citedByCount "22" @default.
• W2601478625 countsByYear W26014786252018 @default.
• W2601478625 countsByYear W26014786252019 @default.
• W2601478625 countsByYear W26014786252020 @default.
• W2601478625 countsByYear W26014786252021 @default.
• W2601478625 countsByYear W26014786252022 @default.
• W2601478625 countsByYear W26014786252023 @default.
• W2601478625 crossrefType "journal-article" @default.
• W2601478625 hasAuthorship W2601478625A5005944401 @default.
• W2601478625 hasAuthorship W2601478625A5015118475 @default.
• W2601478625 hasAuthorship W2601478625A5032711040 @default.
• W2601478625 hasAuthorship W2601478625A5037130722 @default.
• W2601478625 hasAuthorship W2601478625A5044651368 @default.
• W2601478625 hasAuthorship W2601478625A5077539926 @default.
• W2601478625 hasAuthorship W2601478625A5082085481 @default.
• W2601478625 hasAuthorship W2601478625A5082614396 @default.
• W2601478625 hasAuthorship W2601478625A5084517193 @default.
• W2601478625 hasAuthorship W2601478625A5089073003 @default.
• W2601478625 hasAuthorship W2601478625A5091015282 @default.
• W2601478625 hasBestOaLocation W26014786251 @default.
• W2601478625 hasConcept C121608353 @default.
• W2601478625 hasConcept C126322002 @default.
• W2601478625 hasConcept C167734588 @default.
• W2601478625 hasConcept C170493617 @default.
• W2601478625 hasConcept C2777025900 @default.
• W2601478625 hasConcept C2779256057 @default.
• W2601478625 hasConcept C2780394083 @default.
• W2601478625 hasConcept C502942594 @default.
• W2601478625 hasConcept C71924100 @default.
• W2601478625 hasConceptScore W2601478625C121608353 @default.
• W2601478625 hasConceptScore W2601478625C126322002 @default.
• W2601478625 hasConceptScore W2601478625C167734588 @default.
• W2601478625 hasConceptScore W2601478625C170493617 @default.
• W2601478625 hasConceptScore W2601478625C2777025900 @default.
• W2601478625 hasConceptScore W2601478625C2779256057 @default.
• W2601478625 hasConceptScore W2601478625C2780394083 @default.
• W2601478625 hasConceptScore W2601478625C502942594 @default.
• W2601478625 hasConceptScore W2601478625C71924100 @default.
• W2601478625 hasIssue "35" @default.
• W2601478625 hasLocation W26014786251 @default.
• W2601478625 hasLocation W26014786252 @default.
• W2601478625 hasLocation W26014786253 @default.
• W2601478625 hasLocation W26014786254 @default.
• W2601478625 hasOpenAccess W2601478625 @default.
• W2601478625 hasPrimaryLocation W26014786251 @default.
• W2601478625 hasRelatedWork W1444397246 @default.
• W2601478625 hasRelatedWork W2004747172 @default.
• W2601478625 hasRelatedWork W2076049271 @default.
• W2601478625 hasRelatedWork W2078397784 @default.
• W2601478625 hasRelatedWork W2290206685 @default.

• next